CONNECTING AI & BT
PHARMACEUTICAL RESEARCH AND DEVELOPMENT FOR AGING-RELATED DISEASE
Our mission is to accelerate drug discovery and development by converging our ReBADD new artificial intelligence technology and anti-aging drug HTS technology. We will provide AI solution and aging therapeutics with constant innovation.
Development of anti-aging treatment by removing senescent cells based on artificial intelligence
Due to the lack of molecular and biological mechanisms, anti-aging has been difficult to study. Recently, however, the mechanism by which senolysis can control senescent cells opens an entirely new era of anti-aging therapeutics.
We established the company to utilize research and technology related to the efficient control of senescent cells for the development of anti-aging treatments. Under the strategy that artificial intelligence (AI) technology is essential to create a new concept of drugs that has not existed, experts in the field of Biotechnology (BT) and AI founded the company. Major goal of company is to present a new paradigm for anti-aging drug development.
Currently, we (1) establish cell and animal models that can verify anti-aging target discovery technology, (2) use discovery platforms using artificial intelligence and semi high-throughput drug screening, and (3) develop anti-aging gene therapy. Through these technologies, the aim of company is to become a technology leader in the anti-aging industry by preventing or treating aging-related diseases, prolonging lifespan, and improving the quality of life for the elderly.
• New drugs discovery with maximum binding power and chemical properties for target proteins
• Securing active substances based on high-efficiency drug candidate screening technology
• Verification of leading substance effects in cell and animal models
Byung Ju Kim
Professional Experience: Director, Macrogen, Inc./Senior researcher, DGIST./Research staff member, SAIT, Inc./Associate, Albert Einstein College of Medicine
Education: PhD in Biochemistry, The University of Ottawa Medical School
Sung Jin Ryu
Professional Experience: Part leader, Samsung bioepis, Inc./Research staff member SAIT, Inc./Visiting fellow, NCI.
Education: PhD in Biochemistry, Seoul National University College of Medicine
Chi Hyun Park
Current: Assistant Professor, Kangwon National University
Education: PhD in Computer Science, Yonsei University
Current: Associate Professor, DGIST
Education: PhD in Cell & Mol. Biology,
The University of Texas at Austin
Sang Hyun Park
Current: Professor, Yonsei University
Education: PhD in Computer Science,
Current: CEO, Binnobase
Education: EMBA in Life Science Management Program, HTW Berlin/Postdoc in Neuroinflammation, McGill University/PhD in Physiology, The University of Manchester